Oruka Advances ORKA-001 Toward Phase 3 After Positive Psoriasis Data

(RTTNews) - Oruka Therapeutics (ORKA) reported positive Week 16 Phase 2b EVERLAST-B results for ORKA-001 in moderate-to-severe psoriasis.

The high-dose group achieved 61% complete skin clearance (PASI 100) and 86% PASI 90 responses, outperforming placebo.

The treatment showed a favorable safety profile consistent with IL-23 inhibitors.

Oruka plans to advance ORKA-001 into Phase 3 trials in the first half of 2027, with 52-week EVERLAST-A results expected in December 2026.

ORKA on Friday closed at $80.15, down 1.23%. In the pre-market trading, shares are up 1.07% at $81.01.